Creative Medical knee data ‘highly positive,’ says Roth Capital

Roth Capital analyst Jonathan Aschoff says Creative Medical (CELZ) this morning announced “highly positive” results from its pilot study of Ultrasome, a cell-free regenerative therapy for osteoarthritis of the knee. The company announced that 93% of patients had clinically meaningful improvements in mobility and pain reduction without serious adverse events, the analyst tells investors in a research note. Roth believes Ultrasome could have broad applicability across multiple regenerative medicine indications. The firm has a Buy rating on Creative Medical with a $20 price target The stock in late morning trading is down 10c to $2.21.